Eric Mark Green - 07 May 2024 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)

Role
President, CEO and Board Chair, Director
Signature
/s/ Luis Cantarero
Issuer symbol
WST
Transactions as of
07 May 2024
Net transactions value
-$19,782,550
Form type
4
Filing time
09 May 2024, 15:38:13 UTC
Previous filing
08 May 2024
Next filing
02 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WST Common Stock Options Exercise $534,552 +9,316 +6.1% $57.38 162,224 07 May 2024 Direct F1
transaction WST Common Stock Options Exercise $899,948 +15,684 +9.7% $57.38 177,908 07 May 2024 Direct F1
transaction WST Common Stock Options Exercise $2,445,240 +41,000 +23% $59.64 218,908 07 May 2024 Direct F1
transaction WST Common Stock Sale $3,415,636 -9,316 -4.2% $366.64 209,952 07 May 2024 Direct F1, F2
transaction WST Common Stock Sale $5,750,678 -15,684 -7.5% $366.66 193,908 07 May 2024 Direct F1, F2
transaction WST Common Stock Sale $15,032,736 -41,000 -21% $366.65 152,908 07 May 2024 Direct F1, F2
transaction WST Common Stock Options Exercise $536,760 +9,000 +5.9% $59.64 161,908 07 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WST Stock Option (Right to Buy) Options Exercise $0 -9,316 -100% $0.000000* 0 07 May 2024 Common Stock 9,316 $57.38 Direct
transaction WST Stock Option (Right to Buy) Options Exercise $0 -15,684 -100% $0.000000* 0 07 May 2024 Common Stock 15,684 $57.38 Direct
transaction WST Stock Option (Right to Buy) Options Exercise $0 -41,000 -47% $0.000000 45,732 07 May 2024 Common Stock 41,000 $59.64 Direct
transaction WST Stock Option (Right to Buy) Options Exercise $0 -9,000 -20% $0.000000 36,732 07 May 2024 Common Stock 9,000 $59.64 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.
F2 The price reported in Column 4 is a weighted average price.